Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting

被引:0
作者
Jiao, Lijun [1 ]
Tao, Yujian [1 ]
Ding, Huizhen [1 ]
Wu, Feng [1 ]
Liu, Yantong [2 ]
Li, Chuang [3 ]
Li, Feifei [4 ]
机构
[1] Yangzhou Univ, Dept Resp & Crit Care Med, Affiliated Hosp, Yangzhou, Peoples R China
[2] Kunsan Natl Univ, Dept Comp & Informat Engn, Gunsan 54150, South Korea
[3] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47906 USA
[4] Mayo Clin, Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA
关键词
BTK expression; Lung adenocarcinoma (LUAD); Immune microenvironment; Prognostic marker; Immunotherapy; Bioinformatics; TYROSINE KINASE BTK; TEC FAMILY KINASES; TUMOR-MICROENVIRONMENT; WEB SERVER; CANCER; CELLS; LYMPHOCYTES; ISOFORM;
D O I
10.1007/s13205-024-04053-z
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In recent years, as more and more lung-cancer patients have been treated with immunotherapeutic agents, their survival has been prolonged compared to before. It is well known that BTK (Bruton's tyrosine kinase) is predominantly found in cells of the hematopoietic system. However, there is a distinct lack of literature on BTK expression in lung adenocarcinoma (LUAD) patients and its effect on the immune microenvironment. Consequently, the main goal of this investigation was to analyze how BTK expression in lung adenocarcinoma affects its progression, along with its prognostic significance, through the utilization of bioinformatics online resources and publicly available databases. Data on the sequencing results and clinical records of lung adenocarcinoma patients were gathered from The Cancer Genome Atlas (TCGA) database. Based on the expression level of BKT, TCGA categorized lung adenocarcinoma patients into BTK high-expression and low-expression groups. We investigated the effects of BKT on clinicopathologic, genomic, and immunologic characteristics of lung adenocarcinoma patients. We analyzed BTK mRNA expression in tumors and normal tissues using two key resources: Tumor Immuno Estimation Resource 2.0 (TIMER 2.0) and Gene Expression Profiling Interactive Analysis 2 (GEPIA 2). We analyzed the prognosis of the patients using GEPIA2 and validated the results using univariate and multivariate analyses. In addition, we assessed BTK protein expression by Human Protein Atlas (HPA). We sought to elucidate the clinical prognostic significance of BTK in The TCGA using the online tool GEPIA 2. Furthermore, to clarify the biologic roles and pathways linked to BTK, we conducted a genomic enrichment analysis of the information. To predict the proportion of various immune cell infiltrations in the immune microenvironment of lung adenocarcinoma patients diagnosed in the TCGA database, we performed an analysis using the TIMER online tool. Using TIMER and CIBERSORT, the correlation between genes co-expressed with BTK and the corresponding tumor-infiltrating immune cells was explored; finally, the relationship between BTK expression and immune infiltration and immune checkpoints in the TMB group and the high and low groups was analyzed by R language analysis using the TCGA database. The expression of BTK provides some hints about the prognosis of the patients. The high expression of BTK is involved in immune response regulation signaling pathways, leukocyte-mediated immunity, leukocyte intercellular adhesion, graft rejection, and complement. Analysis of the GEPIA 2 database showed that BTK was co-expressed with the genes FGD2, SASH3, NCKAP1L, CD53, ARHGAP30 and LPXN. Increased expression of the above-mentioned genes resulted in increased proportions of CD8 + T cells, memory CD4 + T cells, B cells, macrophages, and dendritic cells, and decreased proportions of Treg cells and TH2 cells. In addition, our study revealed a strong positive correlation between various key immune checkpoints (e.g., PDCD1, CD274, PDCD1LG2, CTLA4, HAVCR2, LAG3, TIGIT, and SIGLEC15) and BTK expression. In conclusion, increased BTK expression in lung adenocarcinoma is closely associated with prolonged survival of lung-cancer patients. Moreover, the genes classified under the BTK high-expression group exhibit significant enrichment in immune-related pathways, suggesting a potential impact on the tumor microenvironment. We investigated the potential of BTK as a tumor suppressor gene in predicting prolonged patient survival. In addition, we further investigated the possibility that BTK further affects the immunotherapeutic response of patients by influencing the microenvironment of tumor immune infiltration, but the relevant mechanisms remain to be further studied.
引用
收藏
页数:19
相关论文
共 57 条
  • [1] A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms
    Al-Toubah, Taymeyah
    Schell, Michael J.
    Cives, Mauro
    Zhou, Jun-Min
    Soares, Heloisa P.
    Strosberg, Jonathan R.
    [J]. NEUROENDOCRINOLOGY, 2020, 110 (05) : 377 - 383
  • [2] Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis
    Bi, Guoshu
    Chen, Zhencong
    Yang, Xiaodong
    Liang, Jiaqi
    Hu, Zhengyang
    Bian, Yunyi
    Sui, Qihai
    Li, Runmei
    Zhan, Cheng
    Fan, Hong
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (07) : 1293 - 1305
  • [3] BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining
    Bi, Ke-Wei
    Wei, Xu-Ge
    Qin, Xiao-Xue
    Li, Bo
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550
  • [5] Targeting BTK in CLL: Beyond Ibrutinib
    Bond, David A.
    Woyach, Jennifer A.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (03) : 197 - 205
  • [6] Tumor-associated stromal cells as key contributors to the tumor microenvironment
    Bussard, Karen M.
    Mutkus, Lysette
    Stumpf, Kristina
    Gomez-Manzano, Candelaria
    Marini, Frank C.
    [J]. BREAST CANCER RESEARCH, 2016, 18
  • [7] A Perspective on Cancer Cell Metastasis
    Chaffer, Christine L.
    Weinberg, Robert A.
    [J]. SCIENCE, 2011, 331 (6024) : 1559 - 1564
  • [8] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
    Chalmers, Zachary R.
    Connelly, Caitlin F.
    Fabrizio, David
    Gay, Laurie
    Ali, Siraj M.
    Ennis, Riley
    Schrock, Alexa
    Campbell, Brittany
    Shlien, Adam
    Chmielecki, Juliann
    Huang, Franklin
    He, Yuting
    Sun, James
    Tabori, Uri
    Kennedy, Mark
    Lieber, Daniel S.
    Roels, Steven
    White, Jared
    Otto, Geoffrey A.
    Ross, Jeffrey S.
    Garraway, Levi
    Miller, Vincent A.
    Stephens, Phillip J.
    Frampton, Garrett M.
    [J]. GENOME MEDICINE, 2017, 9
  • [9] Exploring the Crosstalk between Inflammation and Epithelial-Mesenchymal Transition in Cancer
    Chattopadhyay, Indranil
    Ambati, Rangarao
    Gundamaraju, Rohit
    [J]. MEDIATORS OF INFLAMMATION, 2021, 2021
  • [10] Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery
    Clancy, Trevor
    Dannenfelser, Ruth
    Troyanskaya, Olga
    Malmberg, Karl Johan
    Hovig, Eivind
    Kristensen, Vessela
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (32) : 4716 - 4725